Ascletis Pharma Inc (2VJ) - Total Liabilities

Latest as of December 2025: €132.26 Million EUR ≈ $154.63 Million USD

Based on the latest financial reports, Ascletis Pharma Inc (2VJ) has total liabilities worth €132.26 Million EUR (≈ $154.63 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Ascletis Pharma Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.

Ascletis Pharma Inc - Total Liabilities Trend (2016–2025)

This chart illustrates how Ascletis Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 2VJ total asset value.

Ascletis Pharma Inc Competitors by Total Liabilities

The table below lists competitors of Ascletis Pharma Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Kailuan Energy Chemical Co Ltd SHG:600997	China	CN¥11.39 Billion
SJF Bank A/S CO:SJF	Denmark	Dkr31.48 Billion
Apnimed, Inc. Common Stock NASDAQ:APMD	USA	$85.04 Million
Beijing Hotgen Biotech Co Ltd SHG:688068	China	CN¥278.25 Million
Beijing Capital Development Co Ltd SHG:600376	China	CN¥145.06 Billion
Ladder Capital Corp Class A NYSE:LADR	USA	$4.18 Billion
Paras Defence and Space Technologies Limited NSE:PARAS	India	Rs2.40 Billion
FuelCell Energy Inc NASDAQ:FCEL	USA	$274.87 Million

Liability Composition Analysis (2016–2025)

This chart breaks down Ascletis Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 2VJ net asset quality score to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	15.05	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.07	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.06	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Ascletis Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Ascletis Pharma Inc (2016–2025)

The table below shows the annual total liabilities of Ascletis Pharma Inc from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€132.26 Million ≈ $154.63 Million	-16.51%
2024-12-31	€158.41 Million ≈ $185.20 Million	+6.36%
2023-12-31	€148.94 Million ≈ $174.13 Million	+27.13%
2022-12-31	€117.16 Million ≈ $136.97 Million	+16.13%
2021-12-31	€100.89 Million ≈ $117.95 Million	+18.10%
2020-12-31	€85.42 Million ≈ $99.87 Million	-16.39%
2019-12-31	€102.17 Million ≈ $119.45 Million	+1.98%
2018-12-31	€100.19 Million ≈ $117.13 Million	-17.49%
2017-12-31	€121.42 Million ≈ $141.96 Million	-4.53%
2016-12-31	€127.18 Million ≈ $148.69 Million	--

About Ascletis Pharma Inc

F:2VJ Germany Biotechnology

Market Cap

$1.20 Billion

€1.02 Billion EUR

Market Cap Rank

#8195 Global

#1085 in Germany

Share Price

€0.97

Change (1 day)

+10.23%

52-Week Range

€0.88 - €1.99

All Time High

€1.99